Another cholesterol drug seeks OTC status
Now Pravachol is up to the plate. It too will be unlikely to be approved for OTC status. The pharmaceuticals are desperate to salvage profits in light of their expiring statin patents.
More in Uncategorized
Past Week
-
Medicine’s struggle for inclusivity
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
Unworthiness nearly killed me
-
Your A+ in anatomy and physiology won’t improve the American health care system
-
Breaking free from denial: Embracing the truth
-
AI in American medicine [PODCAST]
-
Past 6 Months
-
Real pain deserves real treatment
-
Medicine’s struggle for inclusivity
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Elite access vs. public scrutiny: Medication disparities exposed
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
When the doctor’s office becomes a confession booth
-
Recent Posts
-
AI in American medicine [PODCAST]
-
Your A+ in anatomy and physiology won’t improve the American health care system
-
The impact of war trauma, the challenge of objectivity, and the power of therapy and storytelling in healing
-
The compassion crisis in U.S. health care
-
Navigating COVID: a journey from academic intensity to healing
-
A tribute to primary care [PODCAST]
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
